Retatrutide – 40mg 

Retatrutide (40 mg) is a next‑generation “triple‑hormone agonist” studied for its ability to activate GLP‑1, GIP, and glucagon receptors simultaneously. This multi‑pathway approach has demonstrated powerful effects on weight loss, blood‑sugar regulation, and fat metabolism. Research shows significant reductions in body weight, along with potential benefits for improving glycemic control and supporting cardiovascular health markers.

For research purposes only. Not intended for human or animal use.